Malaria remains one of the most important infectious diseases in the world, with the greatest
burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The …

Whilst monotherapy is traditionally the preferred treatment starting point for chronic
conditions such as hypertension and diabetes, other diseases require the use of multiple …

Malaria, which is caused by infection of red blood cells with Plasmodium parasites, can be
fatal in non-immune individuals if left untreated. The recent approval of the pre-erythrocytic …

Novel antimalarials are urgently needed to combat rising resistance to available drugs. The
imidazolopiperazine ganaplacide is a promising drug candidate, but decreased …

Background Ganaplacide, also known as KAF156, is among the new antimalarial drug
candidates that have successfully reached Phase III clinical trials, and is proposed in …

Transient receptor potential canonical 5 (TRPC5) is a calcium-permeable non-selective
cation channel involved in various pathophysiological processes, including renal injury …

Background Severe malaria is a life-threatening infection, particularly affecting children
under the age of 5 years in Africa. Current treatment with parenteral artemisinin derivatives …

Over the last 15 years, a small number of paediatric artemisinin-based combination therapy
products have been marketed. These included Riamet® and Coartem® dispersible tablets …

The novel antimalarial ganaplacide combined with lumefantrine solid dispersion formulation
(LUM‐SDF) was effective and well tolerated in the treatment of uncomplicated falciparum …

The introduction of artemisinin combination therapies (ACTs) has significantly reduced the
burden of Plasmodium falciparum malaria, yet the emergence of artemisinin partial …